Leveraging Insulin Sensitizers to Correct the Metabolic Dysfunction Associated with Obesity
Time: 2:30 pm
day: Day Two
Details:
- Metabolic reprogramming through a new mitochondrial target for TZD insulin sensitizers facilitated develop of new insulin sensitizers
- New agents lack tolerability issues of direct transcriptional activators and can fully engage insulin sensitizing pharmacology through the newly identified mitochondrial target
- Metabolic reprogramming occurs in multiple cell types to produce a pleiotropic pharmacology, which importantly includes improved response to viral infections
